Esta información es solo con fines educativos. No constituye consejo médico. Consulte siempre a un profesional de salud cualificado.
Descripción, Dosificación, Efectos secundarios, Contraindicaciones. Data from EMA, URPL, openFDA and other regulatory sources.
| Semaglutide | Liraglutide | |
|---|---|---|
| Sustancias activas | semaglutide | LIRAGLUTIDE |
| Código ATC | A10BJ06 | A10BJ02 |
| Forma | — | SOLUTION |
| Dosificación | — | 18MG/3ML (6MG/ML) |
| Vía de administración | — | SUBCUTANEOUS |
| Fabricante | Novo Nordisk A/S | FRESENIUS KABI USA LLC |
Semaglutide (INN: semaglutide, ATC A10BJ06) and Liraglutide (INN: LIRAGLUTIDE, ATC A10BJ02) differ in active substance, indications, and safety profile. The table above summarizes the clinical differences from regulatory documents.
Combination safety depends on mechanisms and your health profile. Use our interactions checker and always consult your doctor or pharmacist before combining medications.
Both drugs are approved when used per label. Safety is patient-specific — the better choice depends on your condition, other medications, allergies, and comorbidities. Consult a healthcare professional for personalized advice.
Esta información es solo con fines educativos. No constituye consejo médico. Consulte siempre a un profesional de salud cualificado.